The Phase 3 trial initiation timeline (before year-end 2026) is the key catalyst to monitor. No financial data or guidance was provided in this filing.
Price Chart
Executive Summary
Enliven Therapeutics appointed Kristine Ball to its Board of Directors, effective October 14, 2026, and disclosed plans to initiate the pivotal Phase 3 trial of relcobatinib (ELVN-001) before year-end 2026. The appointment adds commercial-stage biopharmaceutical experience as the company transitions toward late-stage development and potential commercialization. No financial results or material changes to operations were reported.
Key Facts
- Board expanded from seven to eight directors; Kristine Ball appointed as Class II director and Audit Committee member.
- Ball receives $45,000/year as outside director plus $10,000/year for Audit Committee service.
- Ball granted stock options with grant date fair value of approximately $650,000, vesting monthly over 36 months.
- Company plans to initiate pivotal Phase 3 trial of relcobatinib (ELVN-001) in previously treated CML before year-end 2026.
- FDA alignment on final design of ENABLE-2 trial was previously announced.
Financial Impact
Director compensation: $55,000 annual cash + ~$650,000 in stock option grant. No impact on revenue or earnings.
Risk Factors
- Clinical trial risks: relcobatinib may fail to demonstrate sufficient safety, efficacy, or differentiated benefit.
- Regulatory risks: FDA may disagree with trial design, endpoints, or require additional studies.
- Financing risk: company may need additional capital to fund operations and clinical development.
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-421761 |
| Document: d13112dex991.htm | 0001193125-26-421761 |
| Document: 0001193125-26-421761-index-headers.html | 0001193125-26-421761 |
| Document: 0001193125-26-421761-index.html | 0001193125-26-421761 |
| Document: 0001193125-26-421761.txt | 0001193125-26-421761 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 21, 2026 4d ago | Insider Cluster | $41.93 | awaiting T+5 | — | $41.29 (−1.53%) |
Oct 19, 2026 6d ago | 144 | $41.25 | awaiting T+5 | — | $41.29 (+0.10%) |
Oct 16, 2026 9d ago | 3 | $38.70 | awaiting T+5 | — | $41.29 (+6.69%) |
Oct 14, 2026 11d ago | 8-K | $39.33 $41.93 | ▲ +6.61% | ▲ +7.63% | $41.29 (+4.98%) |
Sep 21, 2026 4w ago | Insider Cluster | $48.19 $46.51 | ▼ −3.49% | ▼ −2.30% | $41.29 (−14.32%) |
Sep 4, 2026 7w ago | 144 | $59.32 $54.43 | ▼ −8.24% | ▼ −7.03% | $41.29 (−30.39%) |
Aug 19, 2026 9w ago | Insider Cluster | $58.97 $60.50 | ▲ +2.59% | ▲ +1.48% | $41.29 (−29.98%) |
Aug 9, 2026 11w ago | Institutional Cluster | $59.42 $59.54 | ▲ +0.19% | ▲ +0.24% | $41.29 (−30.51%) |
Jul 21, 2026 13w ago | Insider Cluster | $52.85 $52.97 | ▲ +0.23% | ▲ +2.63% | $41.29 (−21.87%) |
Jun 22, 2026 17w ago | 144 | $48.60 $50.85 | ▲ +4.63% | ▲ +3.62% | $41.29 (−15.04%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers